Invest now in myomo, inc.

Please fill in this form to indicate your desired investment amount.

Thank you! Your submission has been received!
Step 2: Open an Account

Please select from one of the following options:

For US Investors:

Open BANQ Account


Complete Via Escrow

Oops! Something went wrong while submitting the form


June 9, 2017

Myomo, Inc. Completes Historic Initial Public Offering

First company to go public on the NYSE MKT under JOBS Act Regulation A+

Cambridge, MA., June 9, 2017 – Myomo, Inc. (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the completion of its initial public offering (IPO) under SEC Regulation A+, raising $4,991,235 through the sale of 665,498 shares of its common stock at a price to the public of $7.50 per share. The Company also closed on a simultaneous private sale of investment units comprised of restricted securities to accredited investors, majority of whom are early investors in Myomo, for total proceeds of $2,925,385.  The combined capital raised is $7,916,620.

Myomo’s common stock is expected to begin trading on the New York Stock Exchange (“NYSE”) MKT on June 12, 2017, under the symbol “MYO” and is the first Regulation A+ issuer to list its securities on a national exchange.  TriPoint Global Equities, LLC, working with its online division BANQ® (, was the lead managing selling agent and bookrunner for the offering. CrowdfundX was the digital marketing agency of record.

“I am very pleased that we have completed a successful IPO and listing on the NYSE MKT, a first under Jumpstart Our Business Startups (JOBS) Act Regulation A+.  The proceeds raised provide Myomo with the resources to continue to invest in the MyoPro® product line, as well as increase our sales and marketing efforts to grow our business domestically and internationally,” said Paul R. Gudonis, Chairman and CEO of Myomo.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

Myomo Allows Patients to Regain Essential Mobility

Myomo produces the MyoPro®, a myoelectric arm orthosis (powered brace) that is the only lightweight wearable device that can restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, spinal cord or nerve injury, or other neuromuscular disability.  With the orthosis, a paralyzed individual can perform activities of daily living including feeding themselves, carrying objects, and doing household tasks and many are able to return to work.

About Myomo

Myomo, Inc. is a commercial stage medical robotics Company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis.  Based on patented technology developed at MIT and the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuromuscular disability such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is provided through clinical relationships with VA medical centers, leading rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”) practices. Several hundred have been successfully used by patients. It is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit

Forward Looking Statements  

This press release contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, and the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Other risks and uncertainties include, among others, risks related to the Company’s liquidity and financial position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

For Myomo:

Investor Relations:

Vivian Cervantes

PCG Advisory



Latest posts
Speaking Engagements
December 10, 2018

Mark Elenowitz will be the moderator covering Smaller Registered and Regulation A Securities12 Offerings at The Securities and Exchange Commission 37th Annual Government-Business Forum on Small Business Capital Formation at Fawcett Center on the campus of The Ohio State University in Columbus, Ohio on December 12, 2018.

Continue Reading
Did BANQ Crack the Mini-IPO Code?
December 10, 2018

Continue Reading
BANQ® Announces Commencement of Horizon Globex $35 million VOX Security Token Offering (STO) Pursuant to Regulation D 506(c)
September 7, 2018

BANQ®, a leading electronic broker-dealer and division of TriPoint Global Equities, LLC, announced today a $35,000,000 Regulation D, Rule 506(c) Security Token Offering (“STO”) for Horizon Globex GmbH of Switzerland ("Globex" or the “Company”). Globex is offering VOX tokens to power Talketh1, its global low-cost communications technology and blockchain enabled crypto-payments service.

Continue Reading